AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Predictors of Vitrectomy Outcomes in Myopic Foveoschisis

RecruitingNAAges 40 Years - 90 YearsAllSingapore National Eye Centre
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This prospective pilot study evaluates factors that predict outcomes after vitrectomy for myopic foveoschisis (MFS), a sight-threatening complication of high myopia that can lead to progressive visual loss, foveal detachment, macular holes, and retinal detachment. Although vitrectomy can relieve traction and improve retinal anatomy, the optimal timing of surgery and the factors associated with visual recovery remain uncertain, particularly in patients with relatively good pre-operative vision. The study will recruit 30 adults aged 40-90 years from Singapore National Eye Centre surgical retina clinics. Participants must have high myopia (worse than -6 dioptres and axial length \>26 mm) with MFS requiring surgery because of progressive vision loss with OCT-confirmed deterioration over six months and/or foveal detachment. Patients with other ocular diseases or conditions that could confoun

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
The target population is 30 adults with high myopia and MFS requiring vitrectomy. inclusion critieria * Be 40-90 years old. * Have high myopia, defined as refractive error worse than -6 dioptres and axial length longer than 26 mm. * Be mentally competent to provide informed consent. * Have MFS that meets clinical criteria for surgical intervention, specifically:progressively worsening vision that correlates with structural OCT deterioration over six months; and/or foveal detachment. exclusion criteria * patients with ocular disorders, prior treatments, or other conditions that could affect structural imaging or functional measurements * corneal opacity * uveitis * dense cataract * vitreous haemorrhage * central serous chorioretinopathy * prior retinal laser photocoagulation or photodynamic therapy * previous or concurrent retinal detachment * retinal dystrophies * macular scarring * retinal vascular occlusion * ocular ischaemic syndrome * ungradable OCT/OCTA imaging. * Patients who are cognitively impaired or prisoners are excluded. * Patients considered poor highly myopic surgical candidates are also excluded, including those with myopic choroidal neovascularisation, macular scar, or complete macular atrophy according to the ATN classification. * Participants may also be discontinued from study assessments if OCT imaging is unsatisfactory or ungradable, or if they are unable to complete functional tests such as microperimetry, contrast sensitivity testing, or M-chart assessment.
๐Ÿ’Š

What it tests

  • pars plana vitrectomy
๐Ÿ“

Where

1 site
Singapore National Eye Centre
Singapore, Singapore
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy